Journal of Alzheimer's Disease最新文献

{"title":"Corrigendum to \"Rapid cognitive assessment: Accuracy and discriminant validity of Mini-Cog and process-based Clock Drawing Test\".","authors":"","doi":"10.1177/13872877251338960","DOIUrl":"10.1177/13872877251338960","url":null,"abstract":"","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"794"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Double product is longitudinally associated with reduced cognitive function in type 2 diabetes with insights from cross-lagged panel analysis and mediation by leucine-rich α-2-glycoprotein 1.","authors":"Serena Low, Angela Moh, Bhuvaneswari Pandian, Huili Zheng, Sharon Pek, Jian-Jun Liu, Keven Ang, Tsz Kiu Kwan, Wern Ee Tang, Ziliang Lim, Tavintharan Subramaniam, Chee Fang Sum, Su Chi Lim","doi":"10.1177/13872877251344881","DOIUrl":"10.1177/13872877251344881","url":null,"abstract":"<p><p>BackgroundElevated systolic blood pressure (SBP) and resting heart rate (RHR) contribute to pathogenesis of diabetic complications. They increase inflammation which can upregulate leucine-rich α-2-glycoprotein 1 (LRG1), an emerging biomarker of cognitive decline.ObjectiveTo examine association between double product (DP, derived from multiplying SBP and RHR) and cognitive function in type 2 diabetes (T2D), with possible mediation by plasma LRG1.MethodsIn this prospective cohort of 1319 patients (mean age 62.5 ± 7.3), plasma LRG1 was measured with enzyme-linked immunosorbent assay. Cognitive function was assessed using Repeatable Battery for Assessment of Neuropsychological Status (RBANS). Cross-lagged panel analysis was done to examine temporal relationship between DP and cognitive function.ResultsBaseline DP was associated with lower baseline RBANS total score (adjusted coefficient = -2.43; 95%CI -4.76, -0.10; p = 0.041). 586 patients were followed up to 8.6 years. Baseline DP was associated with follow-up RBANS total score (adjusted coefficient = -3.80; 95%CI -6.51, -1.10; p = 0.006). It was also associated with lower follow-up RBANS scores in immediate memory and delayed memory with adjusted coefficients -4.38 (95%CI -8.49, -0.28; p = 0.036) and -5.12 (95%CI -9.88, -0.35; p = 0.035) respectively. In cross-lagged panel analysis, standardized effect size of baseline DP on follow-up RBANS total score (β = -0.08; p = 0.002) was larger than that of baseline RBANS total score on follow-up DP (β = -0.04; p = 0.266). LRG1 accounted for 14.7% of the association in mediation analysis (p = 0.035).ConclusionsDP was independently associated with cognitive function with possible mediation by LRG1. DP preceded decline in cognitive function. DP may be potential intervention and monitoring target for prevention of cognitive impairment and possibly Alzheimer's disease in T2D.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"668-677"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Japan-multimodal intervention trial for the prevention of dementia in older people with lifestyle-related diseases: A community-based, 18-month, randomized controlled trial.","authors":"Keiko Ide, Shunsaku Mizushima, Kyoko Saito, Hiroko Suzuki, Yuhei Chiba, Kie Abe, Asuka Yoshimi, Akitoyo Hishimoto, Taro Yamanaka, Takashi Sakurai, Hidenori Arai, Masataka Taguri, Shoko Suzuki, Toshinari Odawara","doi":"10.1177/13872877251344222","DOIUrl":"10.1177/13872877251344222","url":null,"abstract":"<p><p>BackgroundThe prevalence of Alzheimer's disease is increasing in Japan, highlighting the need to establish evidence-based strategies for its prevention.ObjectiveWe aimed to evaluate the effectiveness of a multimodal community-based intervention for Japanese older people with lifestyle-related diseases and to identify challenges in implementing such interventions to prevent dementia in local communities.MethodsAn 18-month randomized controlled trial was conducted among individuals aged 65-85 years with lifestyle-related diseases (hypertension, hyperlipidemia, diabetes, overweight/underweight, smoking), residing in a single apartment complex. Participants were randomly assigned to a multimodal intervention group (group-based physical exercise, nutritional guidance, management of lifestyle-related diseases, and cognitive training) or a control group. The primary outcome was the change in the composite score derived from seven neuropsychological tests. The trial was registered (UMIN000041887: September 24, 2020).ResultsOf 224 screened individuals, 198 were randomized (99 in each group), and 175 (88.4%) completed the 18-month assessment. There was no significant difference between the intervention and control groups in the primary outcome (change in composite test score: 0.25; 95% confidence interval 0.16 to 0.33 versus 0.29; 95% confidence interval 0.20 to 0.38, respectively; <i>p</i> <i>=</i> 0.463). However, a subgroup analysis of participants with mild cognitive impairment showed a significant intervention effect on changes in logical memory, for both immediate (<i>p</i> = 0.041) and delayed recall tasks (<i>p</i> <i>=</i> 0.043).ConclusionsThis multimodal intervention program demonstrated no effectiveness in mitigating cognitive decline. Further research is needed to develop more effective strategies and to better define target populations.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"574-588"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between dementia symptoms and caregiver and relationship health: A prominent role for speech and language.","authors":"Robert W Levenson, Jennifer Merrilees, Maya L Henry, Nina F Dronkers","doi":"10.1177/13872877251340578","DOIUrl":"10.1177/13872877251340578","url":null,"abstract":"<p><p>BackgroundDementia is a significant public health issue globally. People with dementia (PWD) exhibit symptoms in multiple domains (e.g., cognition, emotion, motor, speech/language) that can vary in their impact on the caregiver and the PWD-caregiver relationship.ObjectiveWe assessed the relative impact of various dementia symptoms on caregiver health and well-being and on the PWD-caregiver relationship using a broad sampling of PWD symptoms and caregiver/relationship outcome measures.MethodsData were analyzed from 54 primary caregivers of PWDs who completed seven questionnaires assessing caregiver health and well-being and PWD-caregiver relationship quality. An exploratory factor analysis of these questionnaires revealed two primary factors: (a) General Distress (anxiety, burden, depression, general health, loneliness), and (b) Relationship Quality (interpersonal closeness, relationship satisfaction). Caregivers also rated nine categories of PWD symptoms (memory, executive functions, speech/language, visual/spatial, motor, changes in behavior, sleep, medical/sensory, activities of daily living).ResultsGreater caregiver General Distress was associated with greater PWD speech/language and sleep symptoms. Lower caregiver Relationship Quality was associated (at trend, <i>p</i> < 0.10, levels) with greater PWD speech/language and activities of daily living symptoms. Correlations with the seven individual caregiver outcome measures revealed that speech/language symptoms were the most robust predictors (correlated with five measures), followed by sleep and activities of daily living symptoms (correlated with two measures), and memory, visual/spatial, and motor symptoms (correlated with one measure).ConclusionsFindings highlight the profound adverse effects that PWD speech and language deficits may have on caregivers and underscore the importance of addressing these deficits in dementia care.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"206-217"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity and Alzheimer's disease dementia: Examining inflammatory links to cognitive decline and neuropsychiatric symptoms.","authors":"Carolin Am Koriath, Robert Perneczky","doi":"10.1177/13872877251338467","DOIUrl":"10.1177/13872877251338467","url":null,"abstract":"<p><p>Obesity is recognized as a risk factor for cardiovascular disease, vascular dementia, and Alzheimer's disease dementia (AD dementia). Emerging evidence indicates that obesity in AD patients is associated with heightened neuropsychiatric symptoms, as reflected by inflammatory biomarkers such as C-reactive protein and complement C3. Neuroinflammation, particularly through certain aspects of microglial activation, plays a significant role in AD development and cognitive decline. While further research is warranted to explore these neuroinflammatory pathways as potential therapeutic targets, proactive weight management starting in middle age may help mitigate both cognitive decline and neuropsychiatric symptoms.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"51-53"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The complementary role of automated brain volumetry to stratify ADNI participants within the ATN framework.","authors":"Ilaria Ricchi, Alessandra Griffa, Ricardo Corredor-Jerez, Jonas Richiardi, Jean-François Démonet, Gilles Allali, Bénédicte Maréchal, Olivier Rouaud","doi":"10.1177/13872877251339840","DOIUrl":"10.1177/13872877251339840","url":null,"abstract":"<p><p>BackgroundThe amyloid, tau, neurodegeneration (ATN) framework provides a biological staging model of Alzheimer's disease (AD) using magnetic resonance imaging (MRI), cerebrospinal fluid (CSF), or positron emission tomography (PET) biomarkers. MRI, being non-invasive, accessible, and cost-effective, holds promise as a biomarker.ObjectiveTo evaluate the utility of MRI-based automated brain volumetry in classifying cognitive impairment severity-cognitively unimpaired (CU), mild cognitive impairment (MCI), and dementia-as well as ATN profiles, independently.MethodsWe analyzed 394 subjects from the Alzheimer's Disease Neuroimaging Initiative. First, we assessed how well MRI volumetry stratifies cognitive stages. Next, we tested its ability to distinguish A + T + N+ from A-T-N- individuals while classifying clinical stages. Finally, we evaluated its predictive power for cognitive severity in A + T+ and A-T- subgroups, irrespective of neurodegeneration (N), to examine the added value of volumetry across AT profiles.ResultsMRI volumetry showed comparable performance to established biomarkers in identifying CU, MCI, and dementia, and offered complementary value when combined with phosphorylated tau. Hippocampal and temporal gray matter volumes distinguished A + T + N+ from A-T-N- classes with accuracies of 0.81 and 0.78, respectively. In A + T+ versus A-T- comparisons, the highest classification performance for cognitive severity was observed in the A-T- group.ConclusionsMRI-based brain volumetry can effectively classify cognitive stages and distinguish biological subtypes in AD. It is a promising tool for clinical staging and predicting impairment severity, especially when used alongside phosphorylated tau.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"245-258"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and research focus on autophagy in Alzheimer's disease (2003-2023): A bibliometric study.","authors":"Tianyi Wang, Haochen Jiang, Ruwen Zheng, Chuchu Zhang, Xiumei Ma, Yi Liu","doi":"10.1177/13872877251336442","DOIUrl":"10.1177/13872877251336442","url":null,"abstract":"<p><p>BackgroundAlzheimer's disease (AD) is characterized by amyloid-β plaques and tau aggregates, with autophagy dysfunction playing a key pathogenic role. While autophagy modulation shows therapeutic promise, comprehensive bibliometric analyses are lacking.ObjectiveThis study aims to map the research landscape of autophagy in AD through bibliometric analysis, identifying key trends, contributors, and emerging focus areas.MethodsWe analyzed 4018 publications (2003-2023) from Web of Science using VOSviewer and CiteSpace. Publication trends, influential authors, countries, institutions, and research hotspots were examined through co-occurrence, burst detection, and clustering analyses.ResultsAnnual publications have steadily increased, peaking in 2022. The US led in output and citations, with major contributions from the University of California and New York University. Ralph A. Nixon emerged as the most influential author. Early research (2003-2013) primarily focused on protein degradation mechanisms, whereas recent studies (2014-2023) emphasize mitochondrial dysfunction, apoptosis, and related pathways. Key evolving topics include endoplasmic reticulum stress and chaperone-mediated autophagy, with significant implications for therapeutic innovation.ConclusionsAutophagy plays a critical role in AD pathogenesis and represents a promising therapeutic target. Despite mechanistic advances, clinical translation remains challenging. Future research should prioritize multi-omics integration, drug delivery optimization, and managing risks associated with excessive autophagy activation. These findings provide valuable insights for developing novel AD therapies targeting autophagy.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"5-17"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health economic assessment of technologies for preventing cognitive impairment in elderly people living at home: The case of the digital tablet combined with human support.","authors":"Clément Rimlawi, Abdoul Razak Sawadogo, Gilles Kehoua, Caroline Gayot, Achille Tchalla","doi":"10.1177/13872877251343310","DOIUrl":"10.1177/13872877251343310","url":null,"abstract":"<p><p>BackgroundThe study addresses the challenges of cognitive impairment in an aging population, focusing on the health economic assessment of technologies used by community-dwelling older adults to support cognitive function.ObjectiveTo conduct a systematic review of economic evaluations of digital tablets combined with human support in preventing cognitive impairment in elderly people living at home.MethodsThe following databases were used: PubMed, Scopus, Science Direct, Cochrane library. A total of 45 articles from 2000 to 2024 were identified and screened following the PRISMA guidelines.ResultsOne protocol study and one randomized control trial were included.ConclusionsThe economic evaluation of tablet-based digital intervention for older adults with cognitive impairments is underexplored, necessitating broader research on technology use in this area.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"484-489"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translational computerized clinical decision support systems for Alzheimer's disease: A systematic review.","authors":"Pinya Lu, Mingfeng Chen, Lili Chen, Fan Lin, Hongqin Yang, Yuhua Wang, Xuemei Ding","doi":"10.1177/13872877251343241","DOIUrl":"10.1177/13872877251343241","url":null,"abstract":"<p><p>BackgroundAlzheimer's disease (AD), marked by progressive memory loss and cognitive decline, poses diagnostic challenges due to its multifactorial nature. Therefore, researchers are increasingly leveraging artificial intelligence and data-driven approaches to develop computerized clinical decision support systems (CCDSS), aiming to enhance early detection, improve treatment, and slow disease progression.ObjectiveThis study seeks to conduct a systematic review of the most recently developed AD-CCDSS, delving into their progress and the challenges to guide future development and implementation of CCDSS for AD-related decision-making and intervention strategies.MethodsWe follow the PRISMA 2020 guideline to search for articles published within the past seven years across PubMed, ScienceDirect, IEEE Xplore Digital Library, Web of Science, and Scopus, with Google Scholar as a supplementary source. Key components are then extracted from the selected studies for qualitative analysis, including data modalities, computational modeling approaches, system explainability and interpretability, research priorities, and graphical user interfaces designed for non-technical stakeholders.ResultsAfter searching and removing duplicates, we meticulously selected 55 studies. After reviewing key components of CCDSS, we highlight advancements and potential clinical applications, demonstrating their promise in enhancing decision support. However, despite growing attention to explainability in AD-CCDSS, its clinical applicability remains limited. Moreover, challenges such as multi-center system interoperability and data security remain underexplored, hindering real-world implementation.ConclusionsThis study analyzes recent translational AD-CCDSS, identifying key challenges in advancing CCDSS for clinical applications. It offers insights for researchers to enhance CCDSS development and facilitate their integration into clinical practice.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"443-483"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curcumin's multi-target mechanisms in the treatment of Alzheimer's disease and creative modification techniques.","authors":"Xiaoyuan Meng, Yong Gong, Fengxin Xiao, Zhao Cao, Zheyu Zhuang, Xinan Yi, Juan Wang, Renjun Feng, Chunmei Gong, Panli Ni","doi":"10.1177/13872877251344188","DOIUrl":"10.1177/13872877251344188","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a well-established neurodegenerative disorder characterized by memory impairment, cognitive dysfunction, and behavioral disturbances. With the global population aging, the prevalence of AD continues to rise, presenting significant challenges to both society and healthcare systems. Curcumin, a polyphenolic compound derived from turmeric rhizomes, has demonstrated considerable potential in AD treatment due to its anti-inflammatory, antioxidant, and neuroprotective properties. However, its clinical application remains constrained by chemical instability, poor water solubility, rapid metabolism, and accelerated elimination. To overcome these limitations, various curcumin derivatives have been synthesized, and combination therapy strategies have been explored. This review examines the potential mechanisms through which curcumin may exert therapeutic effects in AD, including the inhibition of neuroinflammation, regulation of tau protein hyperphosphorylation, modulation of amyloid-β peptides, and provision of antioxidant benefits. Additionally, the advantages of curcumin derivatives and combination therapy approaches are discussed, offering novel perspectives and promising strategies for AD treatment. It is anticipated that advancements in drug design and therapeutic approaches will contribute to the development of more effective treatment options for AD.</p>","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"410-426"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}